Celgene Co. (CELG) Shares Bought by Swiss National Bank

Swiss National Bank grew its holdings in shares of Celgene Co. (NASDAQ:CELG) by 1.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,878,596 shares of the biopharmaceutical company’s stock after purchasing an additional 36,000 shares during the period. Swiss National Bank owned approximately 365,619.57% of Celgene worth $419,757,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Janus Henderson Group PLC grew its holdings in shares of Celgene by 4,290.5% in the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after acquiring an additional 8,217,433 shares during the period. BlackRock Inc. grew its holdings in Celgene by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Oaktop Capital Management II L.P. acquired a new stake in Celgene during the 2nd quarter valued at $271,605,000. Arrowstreet Capital Limited Partnership grew its holdings in Celgene by 1,489.2% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after buying an additional 1,787,052 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Celgene by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. Institutional investors own 79.54% of the company’s stock.

Celgene Co. (NASDAQ:CELG) opened at $102.91 on Tuesday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market capitalization of $81,020.00, a price-to-earnings ratio of 24.27, a P/E/G ratio of 0.65 and a beta of 1.77. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the company posted $1.58 EPS. analysts predict that Celgene Co. will post 6.71 earnings per share for the current fiscal year.

A number of brokerages have commented on CELG. Royal Bank of Canada reiterated a “buy” rating and set a $173.00 target price on shares of Celgene in a report on Thursday, October 5th. Morgan Stanley cut Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Thursday, October 5th. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 target price on shares of Celgene in a report on Tuesday, September 26th. Vetr upgraded Celgene from a “hold” rating to a “buy” rating and set a $146.58 target price on the stock in a report on Friday, October 6th. Finally, Zacks Investment Research cut Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $129.98.

COPYRIGHT VIOLATION NOTICE: This story was first posted by BBNS and is owned by of BBNS. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://baseballnewssource.com/markets/celgene-co-celg-stake-increased-by-swiss-national-bank/1817442.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.